Query: treament of asthma

title: Guideline for diagnosis and treament of food allergy in children by "academia of pediatric allergy and asthma society" "Cocuk alerji ve astim akademisi" besin alerjisi tani ve tedavi yontemi
abstract: Besin alerjisi besin proteinlerine karsi gelistirilen spesifik IgE antikorlari araciligi ile ortaya cikan Tip I asiri duyarlilik reaksiyonu olarak tanimlanmaktadir Dunyada oldugu gibi ulkemizde de tum alerjik hastaliklarda oldugu gibi besin alerjisinin gorulme sikligi giderek artmaktadir Anne baba ya da kardeslerinde alerjik rinit bronsiyal astim atopik dermatit ve besin alerjisi gibi alerjik etiolojiye dayali bir hastalik bulunan bebekler besin allerjisi acisindan yuksek risk grubundadirlar Besin alerjisi yonunden risk grubunda bulunan bebeklere uygulanmasi gereken tani ve tedavi yontemlerinin belirlenmesi dogru tani ve tedavinin yapilabilmesinde yararli olacaktir ldquo;Cocuk Alerji ve Astim Akademisi Dernegi rdquo; olarak hazirladigimiz bu protokolun amaci; ldquo;Aile Hekimleri rdquo; ve ldquo;Cocuk Sagligi ve Hastaliklari Uzmanlari rdquo; icin besin alerjilerinin taninmasi ve tedavisi konusunda bir kaynak olarak yol gosterici olmaktir Turk Ped Arfl 2013; 48: 270 4

title: Randomized double blind control multicenter clinical study of levalbuterol hydrochloride in the treament of mild moderate asthma
abstract: To evaluate the efficacy and safety of levalbuterol hydrochloride in the treatment of mild moderate asthma. Randomized double blind,control clinical study was carried out.One hundred twenty two mild moderate asthma patients were randomized to enroll the study.Trial group was treated with oral levalbuterol hydrochloride tablets 1.15 mg thrice daily.Control group was treated with oral salbutamol sulphate tablets 2 mg thrice daily.The therapy window is(14+ 2)d. Comparison with baseline,the first forced expiratory volume vs predicted(FEV1%,the first forced expiratory volume(FEV1)and the first forced expiratory volume vs the forced vital capacity(FEV1/FVC)were obviously improved in trial group.There is significantly statistics difference(P<=0.05).Control group has no significant variance pre and post treatment.Drug adverse reaction of trial group and control group is 12.5% and 15.3%,respectively.There is no marked difference between two groups. Two groups are equivalent in the treatment of mild to moderate asthma,moreover,lung function has been more improved greatly in trial group compared with control group.

title: Clinical efficacy of method of dispelling wind and dispersing lung in treament of cough variant asthma
abstract: To evaluate the therapeutical effect of ShufengZhike decoction(SFZKD) for cough variant  The 260 cases of CVA were recruited, which were divided into two groups randomly: treatment group(130 cases) and control group(130 cases).The treatment group was treated by SFZKD;The control group by slow release theopylline and beclomethasone.Four weeks constituted the course of treatment.The scoring of symptoms,changes of airway responsiveness,the number of peripheric eosinophile(EOS),IL 5 and serum eosinophil cationic protein(ECP) were observed. 1 The total effective rate was 95.4% in treatment group,while 84.7% in control group.There is obviously statistical difference between two groups(P0.05 Statistical analysis by rank sum test .2 There was obvious improvement of cough,expectoration and throaty pruritus after therapy in both groups,but the treatment group was greater than the control group(P0.05).There was no statistical difference on breath lessness and nasal obstruction between two groups(P0.05).3 The Dmin was obviously increased and sGrs decreased in both groups,but the treatment group was greater than the control group(P0.05).4 There were great decreased on EOS,IL 5 and ECP in both groups,but the ECP and IL 5 in treatment group was greater than control group(P0.01).5 There occurred acute episode in 18 cases(14%)in treatment group,while 34 cases(26%)in control group,there is statistical difference between two groups. Method of dispersing wind and ventilating lung possesses a good clinical effect for CVA.The mechanism may be the anti inflammatory in allergic airway and decreasing high airway responsiveness.Moreover,there was greater in long term effect than control group,which decreased the rate of acute episode.

title: Effect of montelukast and dexamethasone on inflammation of asthma
abstract: To study the effect of montelukast(MK)and dexamethasone(Dex)on inflammation of asthma. Asthma model was established and treated with MK or Dex.Bronchoalveolar lavage fluid(BALF) and histopathologic change were observed,IL 5mRNA of lung and bone marrow cells were detected by in situ hybridization,IL 5 immunoreactive cells by immunohistochemistry,and CD34+ and CD3+ of bone marrow cells by flow cytometry. ResultsCompared with asthma group,the number of total cells and eosinophils in BALF of MK group and Dex group were significantly decreased(P0.01),and there also existed significant differences between the two treatment groups(P0.05).It was revealed by pathological examination that there was an extensive airway inflammation in the lung of asthma group accompanied by airway spasm,however,the inflammation of the two treament groups were significantly improved.Data of in situ hybridization suggested that the expression of IL 5mRNA in lung tissue and bone marrow cells of the two treatment groups were significantly decreased than asthma group(P0.05,P0.01),and there were also significant differences between the two treament groups(P0.05).Compared with asthma group,IL 5 immunoreactive cells,CD34+ and CD3+ cells in the bone marrow of treatment groups were significantly decreased(P0.01,P0.05),while there was no significant difference between the two treatment groups(P0.05)  MK and Dex can well inhibit airway inflammation and expression of IL 5mRNA in lung and bone marrow cells,though MK may be inferior to Dex in some aspects.The combined treatment of leukotriene receptor antagonist and glucocorticosteroid may be a new direction for asthma.

title: Progress in Treatment of Asthma
abstract: To investigate the progress in treatment of asthma.Looking up the litera tures home and abroad,then summarizing them.New clinic antiasthmatic drugs ad better effect and less side effect.With the thorough study on mechanism of asthma,the treament of asthma improved.

title: AN INVESTIGATION BY USING BUDESONINDE COMBINED KETONIFEN AND BCG PSN REDUCED TJE INCIDENCE OF ASTHMA AFTER BRONCHIOLITIS.
abstract: To investigate whether it can reduce the incidence of asthma after bronchiolitis treated by inhaling budesoninde combined with administering ketontifen orally and intramuscular injecting BCG PSN.Methods:95 babies were admitted to our hospital from January,2000 to January,2004.All of them were treated routinely at emerging course. They were divided into two groups (47 in treated group and 48 in control group).47 babies in treated group were treated by inhaling budesoninde 100 mg/dose,twice per day for two months,followed by 100 mg/dose,once per day for 4 months.At the same time,these babies were administered ketontifen orally for 3 months and BCG PSN injection for 6 months. The control group ceased therapy after routine treament at emerging course.All these 95 babies were followed up for two years.The incidence of asthma was 4.88%(2/41) in treated group, but 36.36% (16/44) in control group as well. There was significant difference between the two groups(P0.001).The pulmonary function in treated group was improved significantly after treament compared to control group( To the babies with bronchiolitis,it can reduce the incidence of asthma treated by inhaling budesoninde combined with administering ketontifen orally and injecting BCG PSN.

title: Comparative Analysis of CCL18 levels in Children with Allergic Asthma before and after treatment
abstract: To investigate the change and significance of CCL18 level in serum of children with acute allergic asthma before and after treament. 52 patients with acute allergic asthma were divided into 3 groups with severity,and the serum CCL18 level of which were measured respectively by ELISA.Results Serum CCL18 levels in moderate,severe group before treament were significantly higher than that group after treatment(P0.01).Conclusion The level of serum CCL18 maybe related to the severity of asthma attack and it plays an important role in monitoring the therapy of asthma.

title: Effects of dust mite allergen specific immunotherapy on prevention and cure in children with asthma and allergic rhinitis and the reasons of symptom exacerbation during specific immunotherapy
abstract: To evaluate the effects of dust mite allergen specific immunotherapy combined with standardized management on prevention and cure in children with asthma and allergic rhinitis and analyze the reasons of the asthma and allergic rhinitis symptom exacerbation during specific immunotherapy. One hundred and two children with established diagnosis of allergic asthma and allergic rhinitis to dust mite were enrolled in this study from january 2006 to december 2010,of whom 78 children received the treatment with specific immunotherapy(SIT)combined with standardized management for 2 to 4 year(as the test group)and the other 24 served as the control group with inhaled corticosteroids according to Global Initiative for Asthma(GINA)and Allergic Rhinitis and its Impact on Asthma(ARIA)in the same time.At the beginning,6 months,1 year,2 years of the treament and 1 year after the treament,the clinical symptom and acute episode,pulmonery function(Peak Expiratory Flow,PEF)and Chinese children asthma control test(Ch CACT)of the asthmatic children,symptem scores and Visual Analogue Scale(VAS)of allergic rhinitis were analyzed,while respiratory tract infection of all the patients were recorded at the second year and after 1 year of the treatment.The reasons of the asthma and allergic rhinitis symptom exacerbation during dust mite allergen specific immunotherapy were analyzed.The data were analyzed by SPSS15.0.Results Compared with control group,the frequency of acute episode,the frequency of respiratory tract infection in test group were significantly decreased at the 2 years of the treament and 1 year after the treament.The PEFof asthmasic children were obviously improved in the test group at the 2 years of the treament and 1 year after the treament and the Ch CACT were more higher in the test group than the control group at 1 year after the treament.Compared with control group,the symptem scores and VAS of allergic rhinitis were significantly increased in test group at the 6 months,1 year,2 years of the treament and 1 year after the treament.The common reasons of the asthma and allergic rhinitis symptom exacerbation during specific immunotherapy were climatic factor,respiratory tract infection,nasosinusitis and improper room cleared,etc. The dust mite allergen specific immunotherapy can enhance the PEF and Ch CACT of the asthmasic children,can obviously improve the symptem scores and VAS of allergic rhinitis and it is a persistent and effective means on prevention and cure in children with allergic rhinitis and asthma.The climatic factor,respiratory tract infection,nasosinusitis are common reasons of the asthma and allergic rhinitis symptom exacerbation during specific immunotherapy.

title: Asthma Allergy Products for Allergy Relief The Online Allergist
abstract: There are many Asthma allergy Products that can bring allergy relief. See our selection of air purifiers for allergies, allergy bedding and Asthma treament products.

title: Clinical Study Of Cough Variant Asthma On 86 Patien
abstract: To explore clinical characteristics and therapeutic methods of cough variant asthma(CVA) Methods Clinical manifestation diagnosis and treament of 86 case with cough variant asthma(CVA) were analyzed retrospective. CVA was frequently misdiagnosed because of its atypical manifestation The inhalation of glucocorticoid andb_2 agonists had a marked effect on CVA.Conclusions The clinical manifestation of CVA is atypical The key of avoiding missed diagnosis and misdiagnosis is to enhance understanding of the disease Inhalation of glucocorticoid andb_2 agonists is effective to CVA.